A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis (LaunchPAD-RA)
A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination. In RA, citrullinated proteins lead to the production of pathogenic anti-citrullinated peptide antibodies (ACPA).
This is a Phase II, randomised, double-blind, multicentre, 4 arm placebo-controlled study designed to evaluate the efficacy and safety of AZD1163 in ACPA + adults with moderate-to-severely active RA on standard of care (SoC) (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs] or tumour necrosis factor inhibitor [TNFi] +/- csDMARD).
The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention.
Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Caba, Argentina, C1128AAF
- Recruiting
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1015ABO
- Recruiting
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1428DUQ
- Recruiting
- Research Site
-
Córdoba, Argentina, X5000EDC
- Recruiting
- Research Site
-
San Isidro, Argentina, 1643
- Recruiting
- Research Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Recruiting
- Research Site
-
-
-
-
-
Juiz de Fora, Brazil, 36010 570
- Recruiting
- Research Site
-
Pelotas, Brazil, 96040-010
- Recruiting
- Research Site
-
Porto Alegre, Brazil, 90035-903
- Recruiting
- Research Site
-
Porto Alegre, Brazil, 90610-001
- Recruiting
- Research Site
-
Salvador, Brazil, 41820-020
- Recruiting
- Research Site
-
São Paulo, Brazil, 05403-000
- Recruiting
- Research Site
-
São Paulo, Brazil, 04266-010
- Withdrawn
- Research Site
-
-
-
-
-
Haskovo, Bulgaria, 6304
- Recruiting
- Research Site
-
Pleven, Bulgaria, 5800
- Recruiting
- Research Site
-
Sofia, Bulgaria, 1606
- Recruiting
- Research Site
-
Sofia, Bulgaria, 1113
- Recruiting
- Research Site
-
Sofia, Bulgaria, 1612
- Recruiting
- Research Site
-
Sofia, Bulgaria, 1336
- Recruiting
- Research Site
-
-
-
-
Ontario
-
Niagara Falls, Ontario, Canada, L2E 6A6
- Not yet recruiting
- Research Site
-
Ottawa, Ontario, Canada, K1V 1C1
- Not yet recruiting
- Research Site
-
Windsor, Ontario, Canada, N8X 5A7
- Recruiting
- Research Site
-
-
Quebec
-
Trois-Rivières, Quebec, Canada, G9A 3Y2
- Recruiting
- Research Site
-
-
-
-
-
Providencia, Chile, 7510186
- Withdrawn
- Research Site
-
Santiago, Chile, 7500571
- Recruiting
- Research Site
-
Santiago, Chile, 7500587
- Recruiting
- Research Site
-
Temuco, Chile, 4810345
- Recruiting
- Research Site
-
Valdivia, Chile, 5110683
- Recruiting
- Research Site
-
Victoria, Chile, 4720097
- Recruiting
- Research Site
-
Viña del Mar, Chile, 2531172
- Recruiting
- Research Site
-
-
-
-
-
Beijing, China, 100730
- Recruiting
- Research Site
-
Beijing, China, 100144
- Recruiting
- Research Site
-
Changchun, China, 130021
- Recruiting
- Research Site
-
Changsha, China, 410008
- Recruiting
- Research Site
-
Guangzhou, China, 510515
- Recruiting
- Research Site
-
Jiujiang, China, 332000
- Recruiting
- Research Site
-
Kunming, China, 650032
- Not yet recruiting
- Research Site
-
Linyi, China, CN-276003
- Recruiting
- Research Site
-
Nanchong, China, 637000
- Recruiting
- Research Site
-
Panjin, China, 124000
- Recruiting
- Research Site
-
Pingxiang, China, 337055
- Recruiting
- Research Site
-
Shantou, China, 515041
- Recruiting
- Research Site
-
Xuzhou, China, 221009
- Recruiting
- Research Site
-
Yangzhou, China, 225001
- Recruiting
- Research Site
-
Zhengzhou, China, 450000
- Recruiting
- Research Site
-
-
-
-
-
Bad Doberan, Germany, 18209
- Withdrawn
- Research Site
-
Berlin, Germany, 10777
- Recruiting
- Research Site
-
Hamburg, Germany, 20095
- Recruiting
- Research Site
-
Sendenhorst, Germany, 48324
- Recruiting
- Research Site
-
-
-
-
-
Budapest, Hungary, 1027
- Recruiting
- Research Site
-
Budapest, Hungary, 1023
- Recruiting
- Research Site
-
Budapest, Hungary, 1036
- Withdrawn
- Research Site
-
Debrecen, Hungary, 4032
- Recruiting
- Research Site
-
Gyula, Hungary, 5700
- Recruiting
- Research Site
-
Szeged, Hungary, 6725
- Recruiting
- Research Site
-
Székesfehérvár, Hungary, 8000
- Recruiting
- Research Site
-
Veszprém, Hungary, 8200
- Recruiting
- Research Site
-
-
-
-
-
Aomori, Japan, 030-8553
- Recruiting
- Research Site
-
Bunkyō City, Japan, 113-8655
- Recruiting
- Research Site
-
Fukuoka, Japan, 815-8555
- Recruiting
- Research Site
-
Hamamatsu, Japan, 430-0906
- Recruiting
- Research Site
-
Hitachi-Naka, Japan, 312-0057
- Recruiting
- Research Site
-
Iizuka-shi, Japan, 820-8505
- Recruiting
- Research Site
-
Kawachinagano-shi, Japan, 586-8521
- Recruiting
- Research Site
-
Matsuyama, Japan, 790-8524
- Recruiting
- Research Site
-
Meguro-ku, Japan, 152-8902
- Recruiting
- Research Site
-
Miyazaki, Japan, 880-0834
- Recruiting
- Research Site
-
Nagoya, Japan, 457-8511
- Recruiting
- Research Site
-
Okayama, Japan, 700-8557
- Withdrawn
- Research Site
-
Sagamihara-shi, Japan, 252-0315
- Recruiting
- Research Site
-
Sapporo, Japan, 060-0001
- Withdrawn
- Research Site
-
Sasebo-shi, Japan, 857-1195
- Recruiting
- Research Site
-
Sayama-shi, Japan, 350-1305
- Recruiting
- Research Site
-
Yokohama, Japan, 236-0037
- Recruiting
- Research Site
-
-
-
-
-
Chihuahua City, Mexico, 31000
- Recruiting
- Research Site
-
Estado de México, Mexico, 50090
- Recruiting
- Research Site
-
Guadalajara, Mexico, 44160
- Not yet recruiting
- Research Site
-
Guadalajara, Mexico, 44650
- Not yet recruiting
- Research Site
-
Guadalajara, Mexico, 44690
- Not yet recruiting
- Research Site
-
Gustavo A. Madero, Mexico, 07300
- Not yet recruiting
- Research Site
-
Mexicali, Mexico, 021100
- Not yet recruiting
- Research Site
-
Mexico City, Mexico, 06700
- Recruiting
- Research Site
-
Monterrey, Mexico, 64460
- Not yet recruiting
- Research Site
-
Mérida, Mexico, 97070
- Recruiting
- Research Site
-
San Luis Potosí City, Mexico, 78213
- Withdrawn
- Research Site
-
-
-
-
-
Krakow, Poland, 30-727
- Recruiting
- Research Site
-
Krakow, Poland, 30-002
- Recruiting
- Research Site
-
Torun, Poland, 87-100
- Recruiting
- Research Site
-
Warsaw, Poland, 00-874
- Recruiting
- Research Site
-
Wroclaw, Poland, 50-244
- Recruiting
- Research Site
-
-
-
-
-
Caguas, Puerto Rico, 00725
- Recruiting
- Research Site
-
-
-
-
-
Brackenfell, South Africa, 7560
- Withdrawn
- Research Site
-
Cape Town, South Africa, 7500
- Recruiting
- Research Site
-
Durban, South Africa, 4319
- Recruiting
- Research Site
-
Pinelands, South Africa, 7405
- Recruiting
- Research Site
-
Pretoria, South Africa, 0002
- Recruiting
- Research Site
-
Pretoria, South Africa, 0083
- Withdrawn
- Research Site
-
Somerset West, South Africa, 7130
- Recruiting
- Research Site
-
-
-
-
-
Barcelona, Spain, 08041
- Recruiting
- Research Site
-
Barcelona, Spain, 08035
- Recruiting
- Research Site
-
Barcelona, Spain, 08003
- Recruiting
- Research Site
-
Málaga, Spain, 29009
- Recruiting
- Research Site
-
Sabadell, Spain, 08208
- Recruiting
- Research Site
-
Santiago de Compostela, Spain, 15706
- Recruiting
- Research Site
-
Valencia, Spain, 46026
- Recruiting
- Research Site
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76018
- Recruiting
- Research Site
-
Kyiv, Ukraine, 04050
- Recruiting
- Research Site
-
Kyiv, Ukraine, 03037
- Recruiting
- Research Site
-
Kyiv, Ukraine, 04210
- Recruiting
- Research Site
-
Kyiv, Ukraine, 02002
- Recruiting
- Research Site
-
Kyiv, Ukraine, 03049
- Recruiting
- Research Site
-
Uzhhorod, Ukraine, 88000
- Recruiting
- Research Site
-
Vinnytsia, Ukraine, 21029
- Recruiting
- Research Site
-
Vinnytsia, Ukraine, 21018
- Recruiting
- Research Site
-
-
-
-
-
Glasgow, United Kingdom, G31 2ER
- Recruiting
- Research Site
-
Leeds, United Kingdom, LS7 4SA
- Recruiting
- Research Site
-
Luton, United Kingdom, LU4 0DZ
- Recruiting
- Research Site
-
Staffordshire, United Kingdom, WS11 5XY
- Withdrawn
- Research Site
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Recruiting
- Research Site
-
Prescott Valley, Arizona, United States, 86314
- Withdrawn
- Research Site
-
Tucson, Arizona, United States, 85748
- Recruiting
- Research Site
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Research Site
-
San Dimas, California, United States, 91773
- Withdrawn
- Research Site
-
San Leandro, California, United States, 94578
- Recruiting
- Research Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Research Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33435
- Withdrawn
- Research Site
-
Jacksonville, Florida, United States, 32216
- Withdrawn
- Research Site
-
South Miami, Florida, United States, 33143
- Suspended
- Research Site
-
Tampa, Florida, United States, 33607
- Withdrawn
- Research Site
-
Winter Haven, Florida, United States, 33880
- Recruiting
- Research Site
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Recruiting
- Research Site
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Recruiting
- Research Site
-
Willowbrook, Illinois, United States, 60527
- Recruiting
- Research Site
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70605
- Recruiting
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Recruiting
- Research Site
-
Rockville, Maryland, United States, 20850
- Recruiting
- Research Site
-
-
Massachusetts
-
New Bedford, Massachusetts, United States, 02740
- Recruiting
- Research Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64151
- Recruiting
- Research Site
-
St Louis, Missouri, United States, 63131
- Recruiting
- Research Site
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Recruiting
- Research Site
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Recruiting
- Research Site
-
-
Texas
-
Austin, Texas, United States, 78745
- Recruiting
- Research Site
-
Baytown, Texas, United States, 77521
- Recruiting
- Research Site
-
Houston, Texas, United States, 77089
- Recruiting
- Research Site
-
Houston, Texas, United States, 77027
- Recruiting
- Research Site
-
Mesquite, Texas, United States, 75150
- Recruiting
- Research Site
-
Tomball, Texas, United States, 77375
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
-
Inclusion
- Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
- Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
- Have a positive ACPA at screening.
- A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi.
- A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation.
-
Exclusion
- History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible.
- Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AZD1163 Dose 1
Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Experimental: AZD1163 Dose 2
Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Experimental: AZD1163 Dose 3
Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Placebo Comparator: Placebo
Participants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12
Time Frame: Week 12
|
Change from baseline in DAS28-CRP at Week 12. |
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12
Time Frame: Week 12
|
Proportion of participants achieving a 20% improvement in ACR response criteria at Week 12. |
Week 12
|
|
Percentage of Participants Achieving ACR50 at Week 12
Time Frame: Week 12
|
Proportion of participants achieving a 50% improvement in ACR response criteria at Week 12. |
Week 12
|
|
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
Time Frame: Week 12
|
Change from baseline in CDAI at Week 12. |
Week 12
|
|
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
Time Frame: Week 12
|
Change from baseline in SDAI at Week 12. |
Week 12
|
|
Summary statistics to evaluate the PK of AZD1163
Time Frame: Week 0 to Week 24 and Follow-Up
|
AZD1163 concentrations in serum |
Week 0 to Week 24 and Follow-Up
|
|
Summary statistics to evaluate the immunogenicity of AZD1163
Time Frame: Week 0 to Week 24 and Follow-Up
|
ADA (incidence, prevalence, and titres) |
Week 0 to Week 24 and Follow-Up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D9640C00003
- 2025-522076-85 (Other Identifier: EU CT number)
- 167070 (Registry Identifier: IND)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.